top of page
13 janv. 2022
Theranexus reported €12.5 M in cash at end-2021 and set up a new 12-month, €4.2 M equity-linked financing line with IRIS to support its clinical programs, including BBDF-101.
Lyon, Jan 13, 2022 – Theranexus ended 2021 with €12.5 M in cash, supported by prior equity-line drawdowns and tax credit refunds, and aims to secure funding visibility for the next 18 months. The company also established a new €4.2 M equity line with IRIS, structured in twelve tranches, to finance upcoming clinical milestones, particularly in its BBDF-101 Batten disease program
Download Theranexus press release
bottom of page